Product
BYON4228 + Rituximab
Aliases
Truxima
1 clinical trial
1 indication
Indication
lymphomaClinical trial
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 Alone and in Combination With Rituximab to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Relapsed/Refractory CD20 Positive B-cell Non-Hodgkin's Lymphoma (NHL)Status: Recruiting, Estimated PCD: 2024-10-01